Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
40 ≤ age ≤ 75 years with histologically proven PCa
no severe major organ dysfunction
WHO performance status of 0 or 1
no prior cancer chemotherapy
age ≥ 76
severe major organ dysfunction
WHO performance status of >1
prior cancer chemotherapy
Shanghai Jiao Tong University School of Medicine
Lead sponsor
Fudan University
Collaborator
Qilu Hospital of Shandong University
Collaborator